8-K: Day One to Acquire Mersana Therapeutics for $285M

Day One Biopharmaceuticals will acquire Mersana Therapeutics for up to $285 million, expanding its oncology portfolio with a novel ADC for rare cancers.

Summary

• Day One Biopharmaceuticals, Inc. (Parent) has entered into an Agreement and Plan of Merger to acquire Mersana Therapeutics, Inc. (Target) through its wholly owned subsidiary, Emerald Merger Sub, Inc.
• The acquisition is structured as a tender offer for all outstanding shares of Mersana common stock at an offer price of $25.00 per share in cash upfront, plus one contingent value right (CVR) per share.
• The CVRs represent the right to receive additional milestone payments of up to an aggregate of $30.25 per share in cash, bringing the total potential consideration to $55.25 per share.
• The total equity value at closing is approximately $129 million, with a total deal value of up to approximately $285 million, contingent on milestone achievements.
• The primary asset acquired is emiltatug ledadotin (Emi-Le, XMT-1660), a B7-H4-directed antibody-drug conjugate (ADC) currently in Phase 1 development for adenoid cystic carcinoma type 1 (ACC-1).
• ACC-1 is described as a rare, aggressive cancer with high unmet medical need and no approved therapeutic options.
• The transaction is expected to close by the end of January 2026, subject to customary closing conditions, including the tender of a majority of Mersana's outstanding shares and regulatory approvals under the HSR Act.
• Day One expects to finance the acquisition using its existing cash resources, with no additional financing required for Emi-Le's development through potential approval.
• Mersana's current directors and executive officers, along with certain institutional stockholders (Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Investco, LP), collectively owning approximately 8.5% of outstanding shares, have agreed to tender their shares in the offer.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the strategic expansion into a high-unmet-need oncology area with a promising asset, Emi-Le, and the company's strong financial position to fund the acquisition and development without additional financing. The CVR structure also aligns incentives, and the existing product (OJEMDA) shows strong performance.

Positives

• Expands Day One's oncology portfolio with Emi-Le, a potential first-in-class monotherapy for adenoid cystic carcinoma (ACC), a cancer with high unmet need.
• Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for ACC-1, suggesting a potential fast path to registration.
• The acquisition leverages Day One's existing research, development, and commercial capabilities to address underserved, rare, and life-threatening cancers.
• Day One's strong cash position ($451.6 million as of September 30, 2025) is expected to fully fund the acquisition and Emi-Le's development through potential approval without additional financing.
• The CVR structure aligns incentives, with significant payments tied to clinical, regulatory, and commercial milestones for Emi-Le, including up to $30.25 per share.
• The Target Board unanimously determined the merger advisable and in the best interests of Mersana and its stockholders, and recommends stockholders accept the offer.
• Day One is raising its 2025 net product revenue guidance for OJEMDA to $145 $150 million, indicating strong performance of its existing commercial product.

Negatives

• The CVRs are contractual rights only, not transferable except under limited circumstances, and are not registered with the SEC or listed for trading, limiting their liquidity and value certainty.
• There is no assurance that any CVR milestone will be achieved prior to its expiration or termination, meaning the full potential consideration of $30.25 per share may not be realized.
• The acquisition introduces integration risks, including the possibility that the businesses will not be integrated successfully or that integration may be more difficult, time-consuming, or costly than expected.
• The transaction is subject to various conditions, including regulatory approvals and the tender of a sufficient number of shares, which could delay or prevent its completion.

Risks

• Day One's ability to complete the transactions on the proposed terms and schedule, or at all, is uncertain.
• The satisfaction or waiver of various conditions to the consummation of the transactions under the Merger Agreement may not occur.
• Mersana stockholders may not tender sufficient shares in the Offer to meet the Minimum Condition.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Merger Agreement.
• Legal proceedings may be instituted against Day One, Mersana, and/or others relating to the transactions, potentially resulting in significant costs of defense, indemnification, and liability.
• Failure or delay to receive required regulatory approvals relating to the transaction, such as HSR Act clearance, could occur.
• The possibility that competing offers for Mersana will be made exists.
• Disruption from the proposed transactions could make it more difficult to conduct business as usual or maintain relationships with customers, employees, or suppliers.
• Day One may not be able to retain Mersana's employees following the closing of the transaction.
• The businesses may not be integrated successfully, or integration may be more difficult, time-consuming, or costly than expected, or the expected benefits of the transaction may not occur.
• Risks are associated with developing product candidates, including Emi-Le.
• Unforeseen delays may impact the timing of clinical trials and reporting data for Emi-Le.
• There is uncertainty regarding the expected financial performance of Mersana and its product candidates.
• The milestone payments related to the CVRs may never be achieved, and no milestone payment may be made.
• If Day One does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of Day One's shares could decline.

Future Outlook

Day One anticipates that the acquisition of Mersana Therapeutics will position the company for continued success and expansion of its oncology portfolio, adding Emi-Le as a potential first-in-class monotherapy for patients with adenoid cystic carcinoma (ACC). The company believes Emi-Le is well-positioned for potential rapid development and commercialization due to its early anti-tumor activity in Phase 1, its novel targeted mechanism, and the high unmet need in ACC. Day One expects to leverage its existing research, development, and commercial capabilities to advance Emi-Le through potential approval, with the transaction expected to close by the end of January 2026. The company also raised its 2025 net product revenue guidance for OJEMDA to $145 $150 million, reflecting confidence in its existing commercial product.

Management Comments

• Jeremy Bender, Ph.D., chief executive officer of Day One, stated: 'This acquisition will add a potential game-changing new medicine to the Day One portfolio and, if approved, will broaden our opportunities for patient impact and for continued growth and value creation.'
• Bender also noted: 'The addition of the Emi-Le program to our portfolio allows us to leverage the research and development expertise, and the commercial capabilities, that already exist within Day One to address underserved, rare and life-threatening cancers in patients of all ages.'

Industry Context

This acquisition reflects a broader trend in the biopharmaceutical industry where established companies seek to expand their pipelines through strategic M&A, particularly in high-growth, high-unmet-need areas like oncology and rare diseases. Antibody-drug conjugates (ADCs) represent a significant area of innovation, combining the specificity of antibodies with potent cytotoxic agents. Day One's focus on pediatric and rare cancers aligns with a strategy to target niche markets with significant medical needs, potentially allowing for accelerated development pathways and premium pricing. The acquisition of Emi-Le, an ADC targeting B7-H4 for adenoid cystic carcinoma, positions Day One to enter a market with no approved therapies, potentially establishing a new standard of care. This move also diversifies Day One's portfolio beyond its existing pLGG focus, enhancing its long-term growth prospects in the competitive oncology landscape.

Comparison to Industry Standards

• The acquisition of a clinical-stage asset (Emi-Le in Phase 1) for a rare cancer with high unmet need is consistent with industry strategies for pipeline expansion, similar to how larger pharmaceutical companies acquire innovative biotech firms to gain access to novel therapeutic modalities like ADCs.
• The upfront cash payment combined with contingent value rights (CVRs) is a common deal structure in biotech M&A, allowing the acquirer to manage risk by tying a significant portion of the consideration to the successful achievement of development, regulatory, and commercial milestones. This structure is frequently seen in deals involving early-to-mid-stage assets where future success is uncertain.
• The target indication, adenoid cystic carcinoma (ACC), is a rare cancer with an annual U.S. incidence of approximately 1,300 patients. This focus on a well-defined, underserved patient population aligns with strategies employed by companies like Blueprint Medicines (e.g., AYVAKIT for GIST) or Loxo Oncology (acquired by Eli Lilly, e.g., LOXO-292 for RET fusion-positive cancers), which target specific genetic alterations or rare tumor types to achieve accelerated development and market penetration.
• Emi-Le's mechanism as a B7-H4-directed ADC positions it within a rapidly evolving class of oncology drugs. Companies like Seagen (acquired by Pfizer) and Daiichi Sankyo have been leaders in ADC development, demonstrating the potential for these targeted therapies to deliver potent anti-tumor activity with improved specificity compared to traditional chemotherapy. Emi-Le's 'potential first-in-class' status for ACC-1 suggests a high-value opportunity, akin to the market positioning of other novel ADCs entering indications with limited treatment options.

Corporate Governance

Related Party Transactions

• Mersana's current directors and executive officers, along with Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, and BCLS II Investco, LP (collectively, the Support Stockholders), entered into Tender and Support Agreements with Day One and Merger Sub.
• These Support Stockholders, owning approximately 8.5% of outstanding Target Shares as of November 10, 2025, agreed to tender all their shares in the Offer and, if applicable, vote in favor of the Merger.

Stakeholder Impact

• Shareholders of Mersana Therapeutics will receive $25.00 per share in cash upfront, plus potential future payments of up to $30.25 per share via CVRs, offering a premium and potential upside.
• Shareholders of Day One Biopharmaceuticals will see their company's oncology pipeline expanded with a promising, potential first-in-class asset, Emi-Le, for a high-unmet-need cancer, potentially increasing long-term value.
• Employees of Mersana Therapeutics face the risk of retention challenges and integration into Day One's operations, as employment is at-will.
• Patients with adenoid cystic carcinoma (ACC-1) could benefit from the accelerated development and potential commercialization of Emi-Le, offering a new therapeutic option where none currently exist.
• Customers and suppliers of Mersana may experience disruption during the integration process, though Day One aims to maintain business relationships.
• Creditors of Mersana will likely see their obligations assumed by Day One, a financially strong entity, potentially enhancing security.

Next Steps

• Day One Biopharmaceuticals will promptly commence a tender offer to acquire all outstanding shares of Mersana common stock.
• Parent and Merger Sub will make an appropriate filing of a Notification and Report Form pursuant to the HSR Act within 20 business days after November 12, 2025.
• The Merger Sub will merge with and into Mersana Therapeutics, with Mersana continuing as a wholly owned subsidiary of Day One, following the consummation of the tender offer.
• The closing of the Merger is expected to occur by the end of January 2026.
• Day One will continue the clinical development of Emi-Le, leveraging its existing R&D and commercial capabilities.
• Day One will host a conference call and webcast on November 13, 2025, at 8:00 am Eastern Time to discuss the acquisition.

Key Dates

Recommendation

The acquisition of Mersana Therapeutics by Day One Biopharmaceuticals is a highly strategic move that significantly enhances Day One's oncology pipeline with Emi-Le, a potential first-in-class ADC for adenoid cystic carcinoma (ACC-1), a rare cancer with no approved therapies. The early anti-tumor activity of Emi-Le in Phase 1 suggests a promising development path. Day One's strong cash position of $451.6 million allows it to fund the acquisition and Emi-Le's development through potential approval without additional financing, mitigating dilution risk. The CVR structure aligns incentives, providing upside potential tied to clinical and commercial success. Furthermore, Day One's existing product, OJEMDA, is performing strongly, with raised 2025 revenue guidance. This acquisition diversifies Day One's portfolio, leverages its existing capabilities, and positions the company for substantial long-term growth in a high-value oncology segment. While integration risks exist, the strategic benefits and financial strength make this a compelling investment opportunity.

Keywords

Day One Biopharmaceuticals, Mersana Therapeutics, Acquisition, Merger Agreement, Tender Offer, Contingent Value Rights, CVR, Emiltatug Ledadotin, Emi-Le, XMT-1660, Antibody-Drug Conjugate, ADC, B7-H4, Adenoid Cystic Carcinoma, ACC-1, Oncology, Rare Cancer, Biopharmaceutical, Clinical Development, FDA Breakthrough Therapy, Regulatory Approval, Net Sales Milestones